Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis by Owen-Schaub, Laurie B. et al.
 
1717
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/11/1717/07 $2.00
Volume 188, Number 9, November 2, 1998 1717–1723
http://www.jem.org
 
Fas and Fas Ligand Interactions Suppress
Melanoma Lung Metastasis
 
By Laurie B. Owen-Schaub,
 
*
 
 Kenneth L. van Golen,
 
‡
 
 Laurie L. Hill,
 
*
 
 
and Janet E. Price
 
‡
 
From the 
 
*
 
Department of Immunology and the 
 
‡
 
Department of Cell Biology, University of Texas 
M.D. Anderson Cancer Center, Houston, Texas 77030
 
Summary
 
Apoptosis induced by Fas (CD95) ligation is frequently lost during tumor progression; how-
ever, there is no direct evidence to support an association of Fas loss-of-function with meta-
static tumor behavior. To determine whether Fas loss-of-function is critical for acquisition of
the metastatic phenotype, we have compared the ability of Fas-sensitive K1735 murine mela-
nomas to form spontaneous lung metastases in wild-type and Fas ligand–deficient mice. Fas-
sensitive melanoma clones are highly tumorigenic but rarely metastatic in wild-type syngeneic
mice. However, in Fas ligand–deficient mice, both the incidence and number of metastases are
increased. These findings provide the first evidence that Fas–Fas ligand interactions can sup-
press metastasis and that tumor Fas loss-of-function may be causally linked to metastatic pro-
gression.
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A
 
poptosis fundamentally regulates tissue homeostasis.
Impairment of this process can result in aberrant cellu-
 
lar accumulation and increased tumor incidence (1). Fas
(CD95) and Fas ligand (FasL)
 
1
 
 are complementary recep-
tor–ligand proteins that induce apoptosis in many cell
types. Fas is constitutively expressed in many tissues,
whereas FasL is largely restricted to the spleen, lung, large
and small intestine, uterus, testis, and structures of the eye
(2, 3). In the lymphoid population, Fas-induced apoptosis
has been shown to preserve immunologic tolerance, limit
clonal expansion, and maintain immunologic privilege (4).
The potential involvement of Fas in the control of malig-
nant disease has been recognized only recently (5–7). Rele-
vant to the current studies, we (8) and others (9, 10) have
reported that Fas-mediated apoptosis can be lost during
malignant progression as a consequence of Fas downregula-
tion or impaired Fas signaling. Metastasis is the ultimate
step in the process of tumor progression and the principal
cause of death in cancer patients (11). In this report, we
identify Fas loss-of-function as a parameter both necessary
and sufficient for acquisition of the metastatic phenotype.
To produce a clinically significant metastasis, tumor cells
must undergo a step-by-step sequence of events including
tissue invasion at the site of the primary lesion, entrance
into blood and lymphatics, avoidance of host immune de-
fenses, survival in the circulation, adhesion to the vascular
endothelium, extravasation, and growth at a distant site
(12). During the metastatic process, tumor cells are sub-
jected to intense selection pressures such that the majority
die (11, 12). Because each step in the metastatic cascade is
potentially rate limiting, failure to complete a single step
will render a tumor cell nonmetastatic. To determine po-
tential restriction points in the metastatic process, we have
previously investigated the K1735 melanoma system com-
prised of a parental tumor with low metastatic capacity (13)
and clonally derived variants displaying enhanced or re-
duced metastatic properties compared to the parental tu-
mor (14, 15). Using this tumor model, we have shown that
viable, genetically tagged nonmetastatic K1735 tumor cells
can disseminate from the subcutaneous site, survive transit
in the circulation and lymphatics, and extravasate into the
lung microenvironment (16). However, once in the lung,
the nonmetastatic K1735 tumor cells fail to survive and
proliferate, with the subsequent failure to form metastatic
foci (16). An expansive body of literature has correlated
successful metastatic growth with tumor responsiveness to
paracrine and endocrine growth factors (11, 17, 18). How-
ever, in light of more recent evidence implicating apoptosis
in the control of tumor behavior (1, 5–7), we were led to
consider the potential role of tumor responsiveness to apop-
tosis-inducing factors in the microenvironment. Three
 
1
 
Abbreviations used in this paper:
 
 FasL, Fas ligand; LCM, lung-conditioned
medium.
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lines of circumstantial evidence led us to query whether
FasL regulated K1735 metastatic outgrowth in the lung.
First, FasL is present in the lung (2) and has been shown to
induce apoptosis in activated, Fas
 
1
 
 lymphocytes in vivo in
this organ microenvironment (19); second, nonmetastatic
and metastatic K1735 variants differ significantly in their
survival rate in lung conditioned media in vitro (20); and
third, the rate limiting step for K1735 metastasis has been
documented to be outgrowth in the lung (16). Taken to-
gether, these results point toward a potential role for lung-
derived FasL in the control of K1735 tumor growth in the
lung by a process involving Fas-mediated apoptosis.
 
Materials and Methods
 
Fas Expression on Murine Melanoma Clones.
 
Hamster anti–
murine Fas (Jo2) was purchased from PharMingen (San Diego,
CA). PE-conjugated goat anti–hamster antibody was purchased
from Caltag Labs. (Burlingame, CA). Indirect staining was carried
out as previously described (21) using 10
 
6
 
 cells and 0.5 
 
m
 
g anti-
Fas or isotype-matched control and a 1:50 dilution secondary an-
tibody. Fas staining was determined on cells that had been fixed
overnight in 1% paraformaldehyde in PBS using a FACScan
 
Ò
 
(Becton Dickinson, Mountain View, CA) with the windows set
to exclude dead cells and debris. 10,000 cells were examined for
each determination.
 
Fas Sensitivity of Murine Melanoma Clones.
 
Fas sensitivity was
determined using the CD4
 
1
 
 T hybridoma line, 3A9 (22). 3A9
cells were activated by exposure to 10 ng/ml PMA (Sigma
Chemical Co., St. Louis, MO) and 3 
 
m
 
g/ml ionomycin (Sigma
Chemical Co.) for 4 h to upregulate FasL. After activation, 3A9
cells were washed three times and plated in quadruplicate in 96-
well microtiter plates with 
 
51
 
Cr-labeled K1735 targets (5 
 
3
 
 10
 
3
 
cells/well) at a 50:1 effector/target ratio in a final volume of 200
 
m
 
l calcium-free medium. Target cells were 
 
51
 
Cr labeled as previ-
ously reported (23). After 16–18 h incubation at 37
 
8
 
C in a 5%
CO
 
2
 
 atmosphere, 100-
 
m
 
l aliquots of cell-free supernatant were
harvested and radioactivity was measured using an LKB gamma
counter (Amersham Pharmacia Biotech, Piscataway, NJ). Maxi-
mum lysis was determined by incubating 
 
51
 
Cr-labeled targets in 2 N
HCL. Percentage specific target cell lysis was calculated as follows:
100 
 
3
 
 [(experimental lysis 
 
2
 
 spontaneous lysis)/(maximum lysis 
 
2
 
spontaneous lysis)]. Lytic activity of activated 3A9 cells was
blocked by the inclusion of Fas-Fc (data not shown); unactivated
3A9 cells demonstrated no lytic activity. Anti-Fas killing was car-
ried out by plating tumor cells at 5 
 
3
 
 10
 
3
 
/well in triplicate and
adding 100 ng/ml biotinylated anti-Fas (Jo-2 clone; PharMingen)
or biotinylated isotype-matched control antibody (PharMingen)
for 30 min at 37
 
8
 
C then adding 200 ng/ml streptavidin (Jackson
ImmunoResearch Labs., West Grove, PA). After a 48-h culture
cell viability was determined using a tetrazolium reduction (MTT)
assay as described previously (8). Values shown represent the per-
centage of specific cytotoxicity in anti-Fas treated wells after sub-
tracting that of the biotinylated, isotype-matched controls [(1 
 
2
 
mean anti-Fas)/(mean isotype-matched control)] 
 
3
 
 100.
 
Bioassay for FasL in Lung-conditioned Medium and FasL Detection
by Western Blotting.
 
Lung conditioned medium (LCM) was pre-
pared according to the method of Szaniaswska et al. (24) with
modifications. In brief, murine lungs were surgically excised,
washed in cold PBS, cut into 1–2 mm
 
3
 
 pieces, washed in cold
HBSS, and suspended in serum-free MEM with 1% BSA and ro-
tated at 37
 
8
 
C for 6 h. Initial medium was discarded and replaced
with MEM with 0.01% BSA, and the lung fragments were ro-
tated at 37
 
8
 
C for an additional 24 h. After the final rotation, lung
fragments were removed and discarded and the remaining medium
was spun at 15,000 
 
g
 
 for 15 min. The cell-free supernatants were
collected (LCM) and their protein concentration was determined.
For the determination of bioactivity, K1735 cell lines and clones
were plated in media supplemented with 0.3% fetal bovine serum
and 65 
 
m
 
g/ml LCM at 10
 
6
 
 cells/ml and cultured at 37
 
8
 
C, 5%
CO
 
2
 
 for 48 h. After culture, relative cellular viability was deter-
mined using the tetrazolium reduction (MTT) assay as previously
described by our laboratory (21). Background cell death was de-
termined by culturing cells in media supplemented with 0.3% fe-
tal bovine serum alone. Specificity of LCM killing was shown by
inclusion of either Fas-Fc (25) or isotype control–Fc (LT
 
b
 
R-Fc)
at 200 ng/ml for the 48-h culture period. The presence of FasL
protein in LCM was verified by Western blotting. For this proce-
dure, 10-
 
m
 
g aliquots of LCM were separated by 12.5% SDS-
PAGE gel and transferred to nitrocellulose membrane. FasL was
visualized by hybridization with a monoclonal anti-FasL (clone
33; Transduction Laboratories, Lexington, KY) and anti–mouse
horseradish peroxidase was detected using the ECL system (Amer-
sham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK).
 
Detection of FasL in Murine Lung Sections by Immunohistochemis-
try.
 
Frozen sections of murine lung were fixed with 2% formal-
dehyde in PBS for 10 min and washed with PBS. Endogenous
peroxidase was blocked with 3% H
 
2
 
O
 
2
 
 in methanol for 12 min
and the sections were incubated with blocking solution (PBS sup-
plemented with 5% horse serum and 1% goat serum) for 20 min.
Sections were then incubated with FasL-specific antibody, N-20
(Santa Cruz Biotechnologies, Santa Cruz, CA), at a 1:800 dilu-
tion in blocking solution overnight at 4
 
8
 
C. After washing, anti-
body staining was visualized using peroxidase-conjugated goat
anti–rabbit IgG, F(ab
 
9
 
)
 
2
 
 (Jackson ImmunoResearch Labs.) at 1:500 in
blocking solution and stable diaminobenzidine (Research Genet-
ics, Inc., Huntsville, AL). All sections were counterstained with
hematoxylin. Control sections were exposed to blocking solution
alone.
 
Tumor Growth and Metastasis In Vivo.
 
C3H/
 
gld
 
 and C3H/wt
mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). Single cell suspensions of K1735 melanoma cells were pre-
pared by brief incubation of monolayer cultures in 0.02% EDTA
and 0.25% trypsin. Before injection, cells were resuspended in
PBS. For the determination of experimental metastases, 10
 
5
 
 cells
were injected intravenously into the lateral tail vein and meta-
static lung tumor growth was enumerated by visual inspection us-
ing light microscopy 3–5 wk after injection. For the determina-
tion of spontaneous metastases, mice were injected with 5 
 
3
 
 10
 
5
 
cells subcutaneously in the flank. Tumors were aseptically re-
moved when their mean diameter reached 1.5 cm. Metastatic
lung growth was determined by visual inspection using light mi-
croscopy 4–6 wk later. Animal experimentation was performed in
accordance with institutional guidelines and the regulations and
standards of the USDA. Statistical analyses of metastatic incidence
in C3H and C3H/
 
gld
 
 mice were carried out using a 2 
 
3
 
 2 con-
tingency table of the number of mice with metastases versus the
number of mice without metastases using a one-sided 
 
x
 
2
 
 analysis.
Statistical analyses of the number of metastases in C3H versus
C3H/
 
gld
 
 mice were carried out using a Mann-Whitney test.
 
Results and Discussion
 
If lung-derived FasL elicits the apoptosis of nonmeta-
static K1735 tumors in vivo, then metastatic K1735 tumors 
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Figure 1. Fas expression and sensitivity of K1735 melanoma clones. (A) Flow cytometric analyses were carried out as described in Materials and Meth-
ods using a Fas-specific antibody (stippled line) and an isotype-matched control (solid line). Results represent two to five independent determinations for
each clone. (B) FasL-mediated lysis of K1735 clones in overnight 51Cr-release assay as described in Materials and Methods. Values represent mean 6 SEM
of quadruplicate determinations within a single experiment. C10 and C19 killing were shown to be statistically different from that of K1735p and C-23
using Student’s t test (C-10 versus K1735p, P 5 0.017; C-10 versus K1735p, P 5 0.003; C-10 versus C-23, P 5 0.010; C-19 versus C-23, P 5 0.016)
for the data shown. (C) Anti-Fas mediated killing of K1735 clones as described in Materials and Methods. Values represent mean 6 SEM of triplicate de-
terminations within a single experiment. Data are representative of two to five independent determinations for FasL and anti-Fas–mediated killing of
K1735 clones.
 
should lack Fas expression or demonstrate a resistance to-
ward Fas-mediated apoptosis while their nonmetastatic
counterparts should retain Fas sensitivity. To test this
premise, we examined Fas expression and the ability to in-
duce FasL-mediated cell death in vitro in the parental
K1735 tumor (K1735p) and five clonally derived tumor
variants with well-defined metastatic properties. K1735p
(13) and the K1735 C-23 variant (14) rarely metastasize
from a subcutaneously growing tumor site and are consid-
ered to have low metastatic properties. In contrast, the
K1735 clones designated SW-1 and M-2 (15) are highly
metastatic to the lung, whereas their counterparts K1735
C-10 and C-19 are essentially nonmetastatic (14). As
shown in Fig. 1 
 
A
 
, Fas is highly expressed on both the low
and nonmetastatic K1735 tumors (K1735p, C-23, C-10
and C-19), whereas the highly metastatic clones SW-1 and
M-2 lack Fas expression. Although a striking correlation
existed between metastatic behavior and loss of Fas for the
highly metastatic K1735 clones, Fas was equivalently ex-
pressed on both the low and nonmetastatic K1735 tumors.
However, Fas expression does not necessarily predict cellu-
lar sensitivity to FasL-induced apoptosis (8, 9). To deter-
mine whether metastatic behavior in the low and nonmet-
astatic K1735 clones correlated with Fas sensitivity, tumor
targets were 
 
51
 
Cr-labeled and incubated with a FasL-express-
ing effector cell (22), and cytotoxicity was determined as
described in Materials and Methods. As shown in Fig. 1 
 
B
 
,
FasL was cytotoxic for all Fas-positive K1735 tumors. The
nonmetastatic clones C-19 and C-10 were most sensitive
to FasL-induced death, whereas the poorly metastatic tu-
mors K1735p and C-23 were significantly more resistant to
such cytotoxicity. In three out of three experiments, the
low metastatic K1735 tumors were three- to fivefold more
resistant to FasL-induced cytotoxicity than were their met-
astatic counterparts. As expected, the highly metastatic M-2
and SW-1 clones lacking Fas expression were insensitive to
 
FasL-mediated killing. An identical sensitivity profile was
observed when anti–Fas-mediated killing was determined.
Representative clones are shown in Fig. 1 
 
C.
 
 Therefore,
Fas sensitivity rather than Fas expression appears to
uniquely differentiate among those tumors that are highly
metastatic, poorly metastatic, and nonmetastatic. The ob-
servation that Fas sensitivity and metastatic tumor behavior
are inversely correlated suggested a causal effect of Fas loss-
of-function on tumor progression.
Although FasL mRNA is expressed in the lung (2), there
is scant knowledge about the distribution of FasL in this or-
gan. To this end, we carried out immunohistochemical
staining of normal murine lung using a FasL-specific anti-
body. As shown in Fig. 2, 
 
A
 
 and 
 
B
 
, the majority of FasL is
expressed on lung endothelial cells, with rare staining ob-
served in type II pneumocytes as previously reported for
human lung tissue (26). To determine the bioactivity of
lung-expressed FasL, LCM was prepared as previously de-
scribed (24). We have previously reported that LCM con-
tains a cytotoxic factor that differentially induces cell death
in nonmetastatic K1735 tumors while sparing highly meta-
static tumor variants (20). To ascertain whether such cyto-
toxicity was attributable to FasL, we examined LCM bio-
activity against the nonmetastatic K1735 variant C-19 (14).
As shown in Fig. 3, potent, specific FasL-mediated cyto-
toxicity was observed in bioactive LCM preparations. Ap-
proximately 50% of control K1735 C-19 cells were nonvi-
able after a 48-h culture in LCM. Fas-Fc, a competitive
inhibitor of FasL binding (25), almost completely inhibited
LCM-mediated killing of the K1735 C-19 cells. However,
in the presence of a non-FasL binding control such as the
lymphotoxin 
 
b
 
 receptor–Fc (LT
 
b
 
R-Fc), no such reversal
of LCM cytotoxicity was observed. LCM-derived FasL was
additionally verified by immunoblotting. An intense band
of 
 
z
 
40 kD and an additional 32-kD mol mass form repre-
senting the nonglycosylated form of FasL (27) were consis- 
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tently observed in bioactive LCM preparations (Fig. 2 
 
C
 
,
lane 
 
3
 
). Other immunoreactive lower molecular weight
bands, possibly FasL degradation products, were observed
in some preparations (Fig. 2 
 
C
 
, lane 
 
3
 
). In nonbioactive
LCM preparations subjected to multiple freeze–thaw cy-
cles, FasL was virtually undetectable by immunoblotting
(Fig. 2 
 
C
 
, lane 
 
2
 
), substantiating a direct relationship be-
tween LCM bioactivity and FasL protein.
If tumor Fas loss-of-function contributes to the develop-
ment of the metastatic phenotype, then uncoupling Fas–
FasL interactions should permit the metastatic outgrowth
of Fas-sensitive tumors in the lung. To this end, we evalu-
ated the metastatic behavior of the Fas-sensitive K1735 tu-
mor and clones K1735p, C-23, and C-19 (Fig. 1) in nor-
mal (C3H) and FasL-deficient mice (C3H/
 
gld
 
). K1735
tumors were initially injected into the subcutis of both
C3H or C3H/
 
gld
 
 mice and regional growth was moni-
tored. Although palpable tumors were usually detected ear-
lier in C3H/
 
gld
 
 mice than in C3H control mice, measur-
able tumor growth rates were nearly identical between the
two strains. Fig. 4 
 
A
 
 shows one such growth curve using
the K1735p tumor. Furthermore, the mean tumor weights
at the time of surgical resection 28 d after injection were
not statistically different between C3H and C3H/
 
gld
 
 mice
for any of the tumors (Table 1). However, the incidence
and number of spontaneous lung metastases were increased
for all three tumors in mice lacking host-derived FasL. The
most striking enhancement of metastatic incidence and
number of metastases were observed using the K1735p tu-
mor (Fig. 4 
 
B
 
, Table 1). This tumor showed macroscopic
lung metastases in 9 out of 10 C3H/
 
gld
 
 mice (median 18,
range 0–49), whereas only 3 out of 10 wild-type C3H
mice showed evidence of metastatic deposits (median 0,
range 0–25). The increased incidence and number of me-
tastases using the K1735p tumor was highly significant in
C3H/
 
gld
 
 mice compared to C3H controls (difference in
incidence between C3H and C3H/
 
gld P
 
 
 
5 0.0003 using a
one-sided x2 test; difference in number of lung metastases
P , 0.0001 using a Mann-Whitney test). We next exam-
ined the metastatic growth of the clonally derived C-23
variant that, like K1735p, is considered to have low meta-
static properties in C3H mice. As shown in Table 1, C-23
was metastatic in five out of seven C3H/gld mice (median
2, range 0–10), but only one out of five C3H mice (median
0, range 0–20), reflecting a significantly increased incidence
of metastasis in C3H/gld mice compared with wild-type
controls (difference in incidence between C3H and C3H/
gld mice P 5 0.039, a one-sided x2 test). To address the ef-
Figure 2. FasL expression in the lung. Shown are staining of murine lung using isotype-matched control (A)
and FasL-specific antibody (B) visualized by peroxidase-labeled secondary antibodies as described in Materials
and Methods. (C) Western blot analysis of FasL protein in LCM. LCM was subjected to Western blotting us-
ing a FasL-specific antibody as described in Materials and Methods. Lane 1, control lysate from endothelial cells
(Santa Cruz Biotechnologies, Santa Cruz, CA); lane 2, LCM preparation subjected to multiple freeze–thaw cy-
cles lacking FasL bioactivity; lane 3, LCM preparation used for the bioactivity assay shown in Fig. 3. The blot
shown is representative of four independent analyses of LCM.
Figure 3. Loss of K1735 C-19
viability after LCM culture is re-
versed by Fas-Fc. Cells were
plated in media supplemented
with 0.3% fetal bovine serum
and 65 mg/ml LCM. Fas-Fc or
isotype control–Fc (LTbR-Fc)
were added at 200 ng/ml and
relative cellular viability was de-
termined at 48 h using the tetra-
zolium reduction (MTT) assay.
Values shown were normalized
using values of cells cultured in media supplemented with 0.3% fetal bo-
vine serum alone as background. Results are representative of two inde-
pendent experiments.1721 Owen-Schaub et al.
fects of FasL loss-of-function on a nonmetastatic tumor, we
determined lung metastasis of the C-19 clone. As shown in
Table 1, the C-19 clone was spontaneously metastatic in
two out of five C3H/gld mice (range 0–16), whereas one
out of five C3H mice showed evidence of lung deposits
(range 0–1). Although not statistically significant with the
number of animals used for this experiment, these findings
again support a trend for increased incidence and number
of metastases in FasL-deficient animals. Moreover, these
data suggest that the loss of FasL is sufficient for acquisition
of the metastatic phenotype in a nonmetastatic tumor. A
potential criticism of such experiments is that the gld host
microenvironment is more permissive for metastatic tumor
growth irrespective of the loss of FasL. If this were the case,
then Fas-insensitive, metastatic tumors such as M-2 might
also demonstrate increased metastatic capacity in C3H/gld
animals. To test this premise, lung metastatic growth of M-2
was evaluated in C3H and C3H/gld mice. As shown in Ta-
ble 1, lung metastases were not increased in FasL-deficient
mice compared with wild-type mice (difference in lung
metastases P 5 0.421, Mann-Whitney test) documenting
that the gld lung environment per se is not inherently more
permissive for metastatic tumor outgrowth. Taken to-
gether, these results demonstrate that uncoupling of Fas–
FasL interactions can enhance tumor metastasis to organ
sites constitutively expressing FasL (K1735p, C-23) and
may be sufficient to confer metastatic phenotype in a non-
metastatic clone (C-19).
A large body of evidence supports the concept that tu-
mor cell growth and metastasis are dependent upon the in-
teractions of the malignant cell and the host organ environ-
ment (17, 18). Our studies are commensurate with the
interpretation that the interactions of Fas and FasL on the
tumor and host environment, respectively, are critical de-
terminants of tumor cell survival and growth in the meta-
static lung site. Although the successful establishment of
metastatic lesions has been largely correlated with tumor
responsiveness to paracrine growth factors released in spe-
cific organ sites (17, 18), our data indicate an additional role
for apoptosis-inducing factors present in the specific mi-
croenvironment. As Fas-sensitive tumor cells would un-
dergo apoptosis in organ sites constitutively expressing high
Figure 4. Enhanced metastasis of K1735p melanoma cells in FasL-
deficient (C3H/gld) mice. (A) 5 3 105 K1735p cells were injected
subcutaneously into the flank of C3H and C3H/gld mice. At indi-
cated times, tumor diameters were determined by caliper measure.
Results shown represent mean 6 SEM, n 5 10, for each strain. (B)
Gross metastatic tumor growth in two representative lungs from
C3H/gld (left) and C3H control mice (right) subcutaneously injected
with K1735p cells.
Table 1. Metastasis of K1735 Clones in FasL-deficient (C3H/gld) Mice
Tumor clone Mice Tumor weight (g)
Lung metastasis
Incidence (No. of metastases/animal)
mean 6 SEM
K1735p C3H control 2.63 6 1.33 3/10 (0, 0, 0, 0, 0, 0, 0, 2, 11, 25)
C3H/gld 2.58 6 1.38 9/10* (0, 1, 4, 8, 17, 18, 20, 34, 42, 49)‡
C-23 C3H control 2.30 6 0.90 1/5 (0, 0, 0, 0, 20)
C3H/gld 2.47 6 0.65 5/7* (0, 0, 1, 2, 3, 8, 10)
C-19 C3H control 2.20 6 0.70 1/5 (0, 0, 0, 0, 1)
C3H/gld 1.52 6 0.50 2/5 (0, 0, 0, 4, 16)
M-2 C3H control 1.74 6 0.30 5/5 (1, 2, 2, 15, 74)
C3H/gld 1.87 6 0.80 5/5 (3, 4, 12, 16, 50)
Cells were injected subcutaneously into mice and subcutaneous tumors were removed at 1.5-cm diameter and weighed. Incidence is the number of
mice with macroscopic metastases per mice injected. All mice injected had local tumor growth; lung metastatic growth was determined by light mi-
croscopy at 5 wk after removal of subcutaneous tumor or when mice were moribund. 
*Significant difference in incidence of metastases between C3H and C3H/gld mice by x2 test (P 5 0.003 for K1735p; P 5 0.039 for C23).
‡Significant difference in number of metastases between C3H and C3H/gld, P , 0.0001, Mann-Whitney test.1722 Fas and FasL Interactions Suppress Melanoma Metastasis
levels of FasL, we expect a priori that metastatic K1735 tu-
mors preferentially colonizing the lung would be resistant
to Fas-mediated apoptosis. In this report, we document
that four out of four metastatic K1735 melanoma clones
show a loss of Fas expression and/or function compared
with two nonmetastatic clones. We have observed a similar
loss of Fas expression and function in the highly metastatic
K1735 variants C-4 and C-2 (reference 14 and data not
shown). The highly metastatic lung-derived clones SW-1
and M-2 demonstrated a complete loss of both Fas expres-
sion and function, whereas the intermediate metastatic
clones K1735p and C-23 showed a significantly decreased
Fas sensitivity (Fig. 1). That Fas sensitivity was diminished
but not entirely absent in K1735p and C-23 clones with
low metastatic capacity implies that even a partial loss of Fas
function may result in significant biologic consequences, as
has been reported for tumor development in lpr mice
where Fas expression is diminished (5). When Fas–FasL in-
teractions are completely disrupted, such tumors may be-
come significantly more metastatic (Table 1).
Initiation of Fas-mediated apoptosis is complex and
involves, at a minimum, levels of Fas sufficient to insure
optimal receptor cross-linking, the assembly of critical in-
tracellular Fas-associated proteins necessary to initiate the
apoptotic cascade, and the presence or absence of “resis-
tance” proteins such as bcl-xl, Fas-associated phosphatase 1
(FAP-1), and Flice inhibitory protein (FLIP) (9, 28–30). In
this respect, a balance between functional tumor-expressed
Fas and host-derived FasL may be critical parameters regu-
lating the capacity of a particular tumor to grow at a speci-
fied site. For example, Fas expression is absent on the
highly metastatic tumors K1735 SW-1 and M-2, preclud-
ing initiation of the apoptotic cascade by FasL cross-link-
ing. Although Fas is highly expressed on low metastatic
clones K1735p and C-23, postreceptor alterations in Fas
signaling may prevent optimal initiation of the apoptotic
cascade in response to FasL (Fig. 1, A and B). Similarly, the
relative abundance of FasL in the microenvironment may
influence the capacity of a given tumor to survive or un-
dergo apoptosis in disparate organ sites. In support of this
premise, constitutive FasL expression has been reported to
be considerably higher in the murine lung than in the skin
(3), providing a cogent explanation for the apparent co-
nundrum that the Fas-sensitive K1735 tumors grew com-
parably in the subcutis of C3H and C3H/gld mice but were
significantly more metastatic in the lung microenviron-
ment. Although we favor the interpretation that an absence
of FasL in the lung microenvironment permitted the selec-
tive outgrowth of the Fas-sensitive K1735 tumors in C3H/
gld mice, it is conceptually possible that an absence of FasL-
positive immune effector cells encountered in the blood
and lymphatics was also contributory (31–33). Although
the latter possibility seems unlikely in view of the fact that
viable, nonmetastatic tumor cells reach the lung microenvi-
ronment in normal mice (16), we are formally testing this
premise using bone marrow chimeras.
In summary, our studies provide the first evidence that
host-derived FasL can inhibit the malignant potential of
Fas-sensitive tumor cells and suppress organ-specific metas-
tasis. The critical involvement of Fas–FasL in regulation of
the metastatic cascade further underscores the importance
of these proteins in homeostasis and prompts consideration
of strategies aimed toward modification of the tumor–host
environment to prevent metastatic outgrowth.
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